Neogen Announces Sale of Genomics Business to Zoetis
MWN-AI** Summary
Neogen Corporation (NASDAQ: NEOG), a prominent player in food safety solutions, has officially announced a definitive agreement to sell its global genomics business to Zoetis Inc., a leading animal health company, for $160 million, pending regulatory approval and customary closing conditions. This strategic move, originally indicated during a previous portfolio review, aims to streamline Neogen’s operations and focus on core markets that leverage its strengths in food and animal safety. The transaction is anticipated to finalize by the end of the first half of the company's 2027 fiscal year.
Neogen's genomics business, known for its GeneSeek® division, brought in approximately $90 million in sales during fiscal year 2025. CEO Mike Nassif emphasized that this divestiture allows Neogen to accelerate debt reduction and enhance profitability, ensuring that resources are redirected towards areas of the company with significant competitive advantages.
The GeneSeek® business has a distinguished reputation for pioneering advanced DNA testing in both livestock and companion animals. It provides valuable data-driven insights, with products like the Igenity® and GGP® portfolios, advancing genomic prediction and enhancing overall animal performance. The integration of the Encompass™ platform facilitates genomic data management, while continued partnerships support DNA-backed traceability, reinforcing GeneSeek’s commitment to innovation in animal health.
Guggenheim Securities LLC served as the exclusive financial advisor for Neogen in this transaction. Both companies are poised for growth, with Neogen aiming to reinforce its core offerings and Zoetis set to enhance its capabilities within the animal health sector. This deal underscores continued innovation and evolving strategies in the dynamic landscape of food and animal safety.
MWN-AI** Analysis
Neogen Corporation’s recent announcement regarding the sale of its Genomics business to Zoetis Inc. for $160 million marks a strategic pivot towards streamlining its operations and focuses on core competencies in food safety. This divestiture reflects Neogen’s proactive approach in enhancing profitability and alleviating debt—a move that can resonate positively with investors in the long-term.
The strategic rationale behind the sale is compelling. Neogen’s Genomics unit, despite generating approximately $90 million in sales for fiscal year 2025, likely operates in a more specialized niche compared to their robust food safety offerings. By divesting, Neogen can redirect resources and capitalize on its primary market strengths around food and animal safety, where it holds significant competitive advantages. This shift is anticipated to improve overall financial performance and efficiency, a factor that could enhance investor sentiment.
From a financial perspective, the net proceeds from this transaction will primarily be allocated towards debt reduction, which is vital considering the potential risks associated with high leverage. A cleaner balance sheet may provide Neogen with more room to maneuver in future strategic investments or acquisitions, potentially driving growth.
Investors should keep a close watch on the execution of this transition and regulatory approval process. Additionally, while the immediate cash flow impact may be neutral—given the sale price relative to fiscal sales—the long-term benefits of improved operational focus and financial health may contribute to share price appreciation.
For those looking at investments in Neogen, this could be a moment of opportunity. The divestiture aligns with a growing emphasis on specialization and efficiency in businesses, suggesting that Neogen may emerge stronger and more resilient in its core market segments. As always, consider market volatility and external economic factors that may influence future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. (“Zoetis”), the world’s leading animal health company, for $160 million, subject to customary closing adjustments. The planned divestiture, which had been previously announced, was part of the company’s portfolio review strategy to simplify the business and focus on core strategic markets. The transaction is expected to close by the end of the first half of the Company’s 2027 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected to be used primarily for debt reduction. The Genomics business generated approximately $90 million in sales during fiscal year 2025.
“This transaction is part of the company’s strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward,” said Mike Nassif, Neogen’s Chief Executive Officer and President. “Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety. We are committed to a smooth transition for customers, employees and other stakeholders, and believe the business is well positioned to thrive under Zoetis’ ownership.”
Neogen’s Genomics business (GeneSeek ® ) has been a pioneer in advanced DNA testing for livestock and companion animal industries, leveraging a global presence to deliver highly accurate, data-driven insights that contribute to improved animal performance and health, as well as profitability, in the beef, dairy and other industries. Through the flagship Igenity ® and GGP ® portfolio and rapid turnaround times, the business offers returns-focused genomic tools and globally recognized standards in genomic prediction to accelerate herd improvement and enable genomics trait screening. Supported by the Encompass™ platform for genomic data integration and strategic partnerships advancing DNA-backed traceability, GeneSeek is committed to continued innovation and scientific excellence.
Guggenheim Securities LLC acted as exclusive financial advisor to Neogen on the transaction.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit www.zoetis.com .
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the company’s planned divestiture of its Genomics business, the expectation of the transaction closing in the first half of the Company’s 2027 fiscal year, the sale price of $160 million, and the net proceeds being used primarily for debt reduction.
These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.
These risks include, but are not limited to risks relating to the integration of the 3M Food Safety business, risks related to potential tax benefits realized through the 3M transaction, risks related to tariffs and other trade measures, risks related to our international operations and expansion into new geographic markets, risks related to identified material weaknesses in our internal control over financial reporting, risks related to promoting internal growth and identifying and integrating acquisitions, risks related to failure of our systems infrastructure and security breaches of our information systems, risks related to disruption in our manufacturing and service operations, risks related to disruption of third-party package delivery services or pricing increases, risks related to dependence on key suppliers, risks related to the use of distributors for product sales, risks related to the development of new products and technologies, risks related to our ability to maintain a positive reputation, risks related to customer loss, risks related to increased raw material costs, risks related to anti-bribery, trade control, trade sanctions, and anti-corruption laws, risks related to changes in domestic and foreign laws and regulations, risks related to tax audits and changes in tax laws in different jurisdictions, risks related to deterioration in profitability, cash flow, and asset impairments, risks related to competition, risks related to agricultural marketplace, risks related to our substantial indebtedness, risks related to the outcomes of litigation and other legal proceedings, risks related to our ability to obtain and protect intellectual property, risks related to patent infringement challenges, risks related to governmental regulation, risks related to our ability to attract and retain key personnel, risks related to product or service liability claims, risks related to changing political conditions, risks related to climate change, risks related to our inability to meet stakeholder expectations around environmental, social, and governance objectives, risks related to tax legislation, and other factors discussed under the heading “Risk Factors” contained in Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on July 30, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Neogen is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302002729/en/
FAQ**
How is Neogen Corporation (NASDAQ: NEOG) planning to utilize the $160 million from the sale of its Genomics business to Zoetis to enhance its core competencies in food safety solutions?
What are the implications of the divestiture for Neogen Corporation (NASDAQ: NEOG) in terms of its strategic focus on food and animal safety markets?
Given the approximately $90 million sales generated by the Genomics business in fiscal year 2025, how will Neogen Corporation (NASDAQ: NEOG) manage potential revenue loss following the sale?
What potential risks has Neogen Corporation (NASDAQ: NEOG) identified that could affect the closing of the sale of its Genomics business to Zoetis?
**MWN-AI FAQ is based on asking OpenAI questions about Neogen Corporation (NASDAQ: NEOG).
NASDAQ: NEOG
NEOG Trading
-4.24% G/L:
$9.485 Last:
1,225,496 Volume:
$9.46 Open:
